Home › Trial NCT05627115
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
- Trial IDNCT05627115
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorUniversity College, London
- Enrollment80
- Start date2024-03-01
- ConditionsHodgkin Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.